One of the top late-stage drugs Bristol-Myers wants in its $74B Celgene deal faces a ‘roadblock’ — analyst
Bristol-Myers Squibb has another big headache to fret about as it scrambles to rally investor support for its $74 billion acquisition of Celgene.
There’s been some buzz about a patent that Novartis holds on the dose-titration class patent to S1P modulators/agonists. And Credit Suisse analyst Vamil Divan has put that in the spotlight with a note saying the patent poses a threat to any commercialization work involving ozanimod — the big MS drug at Celgene that Bristol-Myers touts as a major reason for its $74 billion buyout bid.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
